David Johnson, MD

Articles

The Role of Radiation, With or Without Chemotherapy, in the Management of NSCLC

Anuradha Chakravarthy, MD;Hak Choy, MD;David Johnson, MD

October 1st 1999

Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The

Paclitaxel, UFT, and Calcium Folinate in Metastatic Breast Cancer

Natalie R. Dickson, MD;Brenda P. Nicholson, MD;David Johnson, MD;Alan Cohen, MD

July 1st 1999

This is a phase I dose-escalation study of uracil and tegafur (in a molar ratio of 4:1 [UFT]) administered in combination with calcium folinate and paclitaxel in metastatic breast cancer. This trial was initiated to 1)

Irinotecan Plus Cisplatin in Patients With Advanced Non- Small-Cell Lung Cancer

Russell Devore Iii, MD;David Johnson, MD;Jeffrey Crawford, MD;Isaiah Dimery, MD;John Eckardt, MD;S. Gail Eckhardt, MD

August 1st 1998

During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung

Cisplatin/Etoposide vs Paclitaxel/Cisplatin/G-CSF vs Paclitaxel/Cisplatin in Non-Small-Cell Lung Cancer

Philip D. Bonomi, MD;Kyungmann Kim, MD;John Kusler, MD;David Johnson, MD

April 1st 1997

A phase III trial conducted by Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with

Cisplatin/Etoposide vs Paclitaxel/Cisplatin/G-CSF vs Paclitaxel/Cisplatin in Non-Small-Cell Lung Cancer

Philip D. Bonomi, MD;Kyungmann Kim, MD;John Kusler, MD;David Johnson, MD

April 1st 1997

A phase III trial conducted by Eastern Cooperative Oncology Group (ECOG) investigators assessed the possible impact of paclitaxel on survival, response, and toxicity in patients with